▶ WOLVERINE · SUBTOPIC · DOSING LITERATURE

WOLVERINE Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of WOLVERINE. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for WOLVERINE reports the following route(s) of administration: Subcutaneous (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of WOLVERINE.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for WOLVERINE of approximately Per-component varies. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of WOLVERINE. Refer to the original publication for full protocol detail.

Sikiric P et al. (2024) reports the WOLVERINE protocol used in BPC-157 stable gastric pentadecapeptide (cytoprotection review), published in Inflammopharmacology. PMID 38980576. See the source for the protocol-level dose range, frequency, and duration. link
Sosne G, Qiu P, Goldstein AL, Wheater M (2010) reports the WOLVERINE protocol used in Biological activities of thymosin beta4 / TB-500 active sites, published in FASEB J. PMID 20179146. See the source for the protocol-level dose range, frequency, and duration. link
Pickart L (2008) reports the WOLVERINE protocol used in The human tri-peptide GHK and tissue remodeling, published in J Biomater Sci Polym Ed. PMID 18644225. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ How is Wolverine blend stored?

Lyophilized at 2–8 °C protected from light. Reconstituted shelf-life is 14 days at 2–8 °C · limited by the GHK-Cu component which degrades faster than non-copper peptides in solution.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · 2–8 °C protected from light

Reconstituted · 2–8 °C, 14 days (limited by GHK-Cu component)

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved as a combined product. Per-component status varies. BPC-157 is on FDA Category 2 of the 503A bulks list.

WADA · BPC-157 prohibited under S0. TB-500 prohibited under S2. GHK-Cu not listed.

◀ WOLVERINE OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19